Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

The antibody–drug conjugate (ADC) field has undergone a renaissance, with substantial
recent developmental investment and subsequent drug approvals over the past 6 years. In …

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …

Glioblastoma, a rare, and highly lethal form of brain cancer, poses significant challenges in
terms of therapeutic resistance, and poor survival rates for both adult and paediatric patients …

Glioblastoma multiforme (GBM) is a lethal disease characterized by an overall survival of
about 1 year, making it one of the most aggressive tumours, with very limited therapeutic …

Glioblastoma (GBM) is the most prevalent and deadly primary brain tumor type, with a
discouragingly low survival rate and few effective treatments. An important function of the …

Simple Summary Glioblastoma is the most common malignant brain tumor associated with a
poor prognosis, with a median survival of 14 months. Despite initial treatment with surgery …

PURPOSE The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
is a phase II platform trial that uses response adaptive randomization and genomic profiling …